AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22632829 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 195
Study 20920295 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolastin-C (60 mg/kg by weekly intravenous infusion for 8 weeks)
Number of subjects: 24
Study 20920295 — intervention group
Group type: COMPARATOR
Intervention: Prolastin (60 mg/kg by weekly intravenous infusion for 8 weeks)
Number of subjects: 24
Study 20920295 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolastin-C (double-blind treatment phase only)
Number of subjects: 24
Study 20920295 — intervention group
Group type: COMPARATOR
Intervention: Prolastin
Number of subjects: 24
Study 18567886 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended transsternal thymectomy combined with the prednisone protocol
Number of subjects: 0
Study 18567886 — intervention group
Group type: COMPARATOR
Intervention: Prednisone protocol alone
Number of subjects: 0
Study 15625603 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F‐FDG PET
Number of subjects: 84
Study 15625603 — intervention group
Group type: COMPARATOR
Intervention: MRI
Number of subjects: 84
Study 15625603 — intervention group
Group type: EXPERIMENTAL
Intervention: Early phase (40 min) 18F‐FDG PET
Number of subjects: 84
Study 15625603 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed phase (3 h) 18F‐FDG PET
Number of subjects: 84
Study 12190759 — intervention group
Group type: EXPERIMENTAL
Intervention: ProSeal laryngeal mask airway
Number of subjects: 20
Study 12190759 — intervention group
Group type: COMPARATOR
Intervention: Standard laryngeal mask airway
Number of subjects: 20
Study 10325828 — intervention group
Group type: EXPERIMENTAL
Intervention: Alveolar recruitment strategy with PEEP 15 cm H2O and tidal volume of 18 ml kg‐1 or peak inspiratory pressure of 40 cm H2O
Number of subjects: 30
Study 10325828 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP 5 cm H2O after initial control period without PEEP
Number of subjects: 30
Study 10325828 — intervention group
Group type: COMPARATOR
Intervention: ZEEP (no PEEP)
Number of subjects: 30
Study 8931831 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 24
Study 8931831 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril
Number of subjects: 24
Study 8931831 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 24
Study 1582305 — intervention group
Group type: EXPERIMENTAL
Intervention: Early adjunctive corticosteroids for Pneumocystis pneumonia
Number of subjects: 28
Study 4076329 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine 250 mg orally
Number of subjects: 12
Study 4076329 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine 50 mg intravenously
Number of subjects: 12
Study 4076329 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green 0.15 mg/kg intravenously
Number of subjects: 12
Study 30394919 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysate temperature of 35°C
Number of subjects: 21
Study 30394919 — intervention group
Group type: COMPARATOR
Intervention: Dialysate temperature of 37°C
Number of subjects: 21
Study 29577973 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (4 g)
Number of subjects: 85
Study 29577973 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (200 mg)
Number of subjects: 85
Study 29577973 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (4 g) + Coenzyme Q10 (200 mg)
Number of subjects: 85
Study 29577973 — intervention group
Group type: COMPARATOR
Intervention: Control (4 g olive oil)
Number of subjects: 85
Study 26446328 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg solifenacin per day
Number of subjects: 119
Study 26446328 — intervention group
Group type: COMPARATOR
Intervention: 4 mg fesoterodine per day
Number of subjects: 119
Study 24092385 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 44
Study 24092385 — intervention group
Group type: COMPARATOR
Intervention: Calcineurin inhibitor (CsA)
Number of subjects: 44
Study 22460670 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold weights (GW)
Number of subjects: 22
Study 22460670 — intervention group
Group type: COMPARATOR
Intervention: Platinum chain
Number of subjects: 22
Study 20001977 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour infusion of short acting insulin
Number of subjects: 65
Study 20001977 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 65
Study 17588297 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam HCl
Number of subjects: 0
Study 15562352 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI follow-up in patients with congenital anophthalmos
Number of subjects: 18
Study 15562352 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with orbital expanders
Number of subjects: 18
Study 15562352 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI orbital volumetry
Number of subjects: 18
Study 15562352 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-inflating high, hydrophilic hydrogel expanders
Number of subjects: 18
Study 11834235 — intervention group
Group type: EXPERIMENTAL
Intervention: MPA+E(2)C injection on Day 7 of the menstrual cycle (delayed-injection group, n = 117)
Number of subjects: 158
Study 11834235 — intervention group
Group type: COMPARATOR
Intervention: MPA+E(2)C injection on Day 5 of the menstrual cycle (control group, n = 41)
Number of subjects: 158
Study 8396204 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (n = 6)
Number of subjects: 11
Study 8396204 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B and flucytosine (n = 5)
Number of subjects: 11
Study 8396204 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 8)
Number of subjects: 11
Study 3526789 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive pressure ventilation at 8 times per minute
Number of subjects: 11
Study 3526789 — intervention group
Group type: COMPARATOR
Intervention: Continuous positive pressure ventilation at 16 times per minute
Number of subjects: 11
Study 30021076 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral epinephrine
Number of subjects: 8014
Study 30021076 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 8014
Study 27064136 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin trometamol 3 g orally on days 1, 3, and 5
Number of subjects: 126
Study 27064136 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone 250 mg intramuscularly plus azithromycin 1 g orally as a single dose
Number of subjects: 126
Study 25403144 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentalization-Based Treatment in a day hospitalization setting (MBT-DH)
Number of subjects: 0
Study 25403144 — intervention group
Group type: COMPARATOR
Intervention: Mentalization-Based Treatment in an intensive outpatient setting (MBT-IOP)
Number of subjects: 0
Study 23372680 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC)
Number of subjects: 81
Study 23372680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 21769873 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (100 mg kg(‐1))
Number of subjects: 20
Study 21769873 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (50 mg kg(‐1))
Number of subjects: 20
Study 21769873 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (12.5 mg kg(‐1))
Number of subjects: 20
Study 21769873 — intervention group
Group type: COMPARATOR
Intervention: Folic acid supplementation (0 mg kg(‐1))
Number of subjects: 20
Study 21769873 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (any level)
Number of subjects: 20
Study 18509121 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg prucalopride
Number of subjects: 620
Study 18509121 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg prucalopride
Number of subjects: 620
Study 18509121 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 620
Study 18509121 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg and 4 mg prucalopride
Number of subjects: 620
Study 17142503 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally administered amoxicillin
Number of subjects: 857
Study 17142503 — intervention group
Group type: EXPERIMENTAL
Intervention: Oximetry data
Number of subjects: 857
Study 17142503 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical parameters assessment after 24 hours
Number of subjects: 857
Study 17142503 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline vital signs, symptoms, and laboratory data
Number of subjects: 857
Study 12911410 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 132
Study 12911410 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensively hydrolysed formulas
Number of subjects: 132
Study 12911410 — intervention group
Group type: COMPARATOR
Intervention: Cow's milk and/or formula
Number of subjects: 132
Study 10631825 — intervention group
Group type: EXPERIMENTAL
Intervention: Castor oil (60 mL)
Number of subjects: 103
Study 10631825 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 103
Study 9182975 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 1000
Study 9182975 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study 9182975 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen and Placebo (combined outcomes)
Number of subjects: 1000
Study 1398851 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloramphenicol succinate (CS) 50 mg/kg/day
Number of subjects: 40
Study 1398851 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloramphenicol succinate (CS) 75 mg/kg/day
Number of subjects: 40
Study 1398851 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloramphenicol succinate (CS) 100 mg/kg/day
Number of subjects: 40
Study 1398851 — intervention group
Group type: COMPARATOR
Intervention: Non-typhoidal illnesses (control group)
Number of subjects: 40
Study 2881900 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 11
Study 2881900 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 11
Study 2881900 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 11
Study 2881900 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol plus Nifedipine
Number of subjects: 11
Study 2881900 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol plus Nifedipine
Number of subjects: 11
Study 29571095 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral interventions (specific types not detailed)
Number of subjects: 26495
Study 29571095 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard invitation letter)
Number of subjects: 26495
Study 27033722 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally targeted intervention for diabetes management
Number of subjects: 248
Study 23881909 — intervention group
Group type: EXPERIMENTAL
Intervention: Group problem-solving therapy (PST)
Number of subjects: 58
Study 23881909 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 58
Study 24068395 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 93
Study 24068395 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiochemotherapy
Number of subjects: 93
Study 24068395 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiochemotherapy with molecular anti-EGFR target therapy
Number of subjects: 93
Study 24068395 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 93
Study 24068395 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunohistochemical staining for EGFR
Number of subjects: 93
Study 24068395 — intervention group
Group type: EXPERIMENTAL
Intervention: Ki67 index
Number of subjects: 93
Study 24068395 — intervention group
Group type: EXPERIMENTAL
Intervention: p53 protein expression
Number of subjects: 93
Study 21712336 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentivised indicators
Number of subjects: 653500
Study 21712336 — intervention group
Group type: COMPARATOR
Intervention: Non-incentivised indicators
Number of subjects: 653500
Study 19912736 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenyi Capsule combined with gemcitabine plus cisplatin (GP) regimen
Number of subjects: 60
Study 17127615 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced scanning
Number of subjects: 20
Study 17127615 — intervention group
Group type: COMPARATOR
Intervention: Traditional scanning
Number of subjects: 20
Study 15247911 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-valent pneumococcal conjugate vaccine (PncCV)
Number of subjects: 37107
Study 15247911 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37107
Study 11439963 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant alpha-galactosidase A
Number of subjects: 58
Study 11439963 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 9296467 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin (low-molecular-weight heparin)
Number of subjects: 1482
Study 9296467 — intervention group
Group type: COMPARATOR
Intervention: Dalteparin (lower dose)
Number of subjects: 1482
Study 9296467 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin (twice-daily administration)
Number of subjects: 1482
Study 9296467 — intervention group
Group type: COMPARATOR
Intervention: Dalteparin (lower once-daily dose)
Number of subjects: 1482
Study 8395472 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% high complex/high starch and fibre (HC/HSF‐CHO) and 20% fat (group 1; 11 subjects)
Number of subjects: 25
Study 8395472 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% high simple/high natural fibre (HS/HNF‐CHO) and 20% fat (group 2; 7 subjects)
Number of subjects: 25
Study 8395472 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% CHO (L‐CHO) and 60% fat (group 3; 7 subjects)
Number of subjects: 25
Study 3530305 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral lamotrigine (240 mg)
Number of subjects: 0
Study 3530305 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3530305 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (20 mg)
Number of subjects: 0
Study 31296073 — intervention group
Group type: EXPERIMENTAL
Intervention: Poractant alpha
Number of subjects: 62
Study 31296073 — intervention group
Group type: EXPERIMENTAL
Intervention: Beractant
Number of subjects: 62
Study 31296073 — intervention group
Group type: EXPERIMENTAL
Intervention: Calfactant
Number of subjects: 62
Study 31296073 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 62
Study 28726590 — intervention group
Group type: EXPERIMENTAL
Intervention: ICE protocol
Number of subjects: 167
Study 28726590 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-/moderate-dose hypertonic saline
Number of subjects: 167
Study 28726590 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol
Number of subjects: 167
Study 28726590 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hyperventilation (adjusted partial pressure of carbon dioxide 30-35 mm Hg)
Number of subjects: 167
Study 28726590 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressors to maintain cerebral perfusion
Number of subjects: 167
Study 26953566 — intervention group
Group type: EXPERIMENTAL
Intervention: Debriefing-on-demand
Number of subjects: 8
Study 26953566 — intervention group
Group type: COMPARATOR
Intervention: Conventional debriefing
Number of subjects: 8
Study 24486426 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported Employment (SE) intervention (n=81)
Number of subjects: 157
Study 24486426 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (C) (n=76)
Number of subjects: 157
Study 22438027 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus plus prednisone (n=34)
Number of subjects: 70
Study 22438027 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine plus prednisone (n=36)
Number of subjects: 70
Study 19728091 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based gender-specific drug prevention program (12 sessions)
Number of subjects: 236
Study 19728091 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 236
Study 18281663 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week cardiovascular and strength training exercise intervention
Number of subjects: 101
Study 18281663 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 101
Study 15718840 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenotype susceptibility testing (PHENO)
Number of subjects: 238
Study 15718840 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 238
Study 15718840 — intervention group
Group type: COMPARATOR
Intervention: Both groups (PHENO and SOC)
Number of subjects: 238
Study 14521596 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemaccel
Number of subjects: 55
Study 14521596 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelofusine
Number of subjects: 55
Study 14521596 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin
Number of subjects: 55
Study 14521596 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 55
Study 10492858 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice weekly ECT
Number of subjects: 48
Study 10492858 — intervention group
Group type: COMPARATOR
Intervention: Three times weekly ECT
Number of subjects: 48
Study 8698227 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric permeability measured by oral or duodenal administration of a triple sugar solution (20 g sucrose, 10 g lactulose, 5 g mannitol in 100 mL water)
Number of subjects: 43
Study 8698227 — intervention group
Group type: EXPERIMENTAL
Intervention: Intestinal permeability measured by lactulose/mannitol test
Number of subjects: 43
Study 8698227 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 43
Study 1894758 — intervention group
Group type: EXPERIMENTAL
Intervention: 150‐mg phenylpropanolamine
Number of subjects: 16
Study 1894758 — intervention group
Group type: EXPERIMENTAL
Intervention: 75‐mg phenylpropanolamine
Number of subjects: 16
Study 1894758 — intervention group
Group type: EXPERIMENTAL
Intervention: 75‐mg phenylpropanolamine plus 400‐mg caffeine
Number of subjects: 16
Study 1894758 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 6225150 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimelidine (75-300 mg/day)
Number of subjects: 229
Study 6225150 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (dosage not specified)
Number of subjects: 229
Study 6225150 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 229
Study 6225150 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimelidine
Number of subjects: 229
Study 6225150 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 229
Study 31862664 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait training splint
Number of subjects: 23
Study 31862664 — intervention group
Group type: COMPARATOR
Intervention: Baseline walking speed
Number of subjects: 23
Study 30594339 — intervention group
Group type: EXPERIMENTAL
Intervention: TKA communication checklist
Number of subjects: 127
Study 30594339 — intervention group
Group type: COMPARATOR
Intervention: Standard of care communication
Number of subjects: 127
Study 27841155 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilaprisan 1 mg
Number of subjects: 100
Study 27841155 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilaprisan 5 mg
Number of subjects: 100
Study 27841155 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilaprisan 15 mg
Number of subjects: 100
Study 27841155 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilaprisan 30 mg
Number of subjects: 100
Study 27841155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 26925155 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ART
Number of subjects: 755
Study 25186261 — intervention group
Group type: EXPERIMENTAL
Intervention: tiotropium
Number of subjects: 255
Study 25186261 — intervention group
Group type: EXPERIMENTAL
Intervention: fluticasone propionate/salmeterol combination
Number of subjects: 255
Study 25186261 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 255
Study 22247116 — intervention group
Group type: COMPARATOR
Intervention: Surgical castration pre-weaning (CON)
Number of subjects: 75
Study 22247116 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact bulls (BULL)
Number of subjects: 75
Study 22247116 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulls castrated by the Callicrate Bander (BAN)
Number of subjects: 75
Study 22247116 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulls castrated by the Henderson Castrating Tool (HEN)
Number of subjects: 75
Study 22247116 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulls castrated surgically utilizing an emasculator (SUR)
Number of subjects: 75
Study 19164356 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 500 microg x day(‐1)
Number of subjects: 32
Study 19164356 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 1,000 microg x day(‐1)
Number of subjects: 32
Study 19164356 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 320 microg x day(‐1)
Number of subjects: 32
Study 19164356 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 640 microg x day(‐1)
Number of subjects: 32
Study 19164356 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate 1,000 microg x day(‐1) vs Ciclesonide 320 microg x day(‐1)
Number of subjects: 32
Study 19164356 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate 1,000 microg x day(‐1) vs Ciclesonide 640 microg x day(‐1)
Number of subjects: 32
Study 19164356 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate 500 microg x day(‐1) vs Ciclesonide 320 microg x day(‐1)
Number of subjects: 32
Study 19164356 — intervention group
Group type: COMPARATOR
Intervention: Ciclesonide 640 microg x day(‐1) vs Fluticasone propionate 1,000 microg x day(‐1)
Number of subjects: 32
Study 16428539 — intervention group
Group type: EXPERIMENTAL
Intervention: SCH 1 mg/kg ideal body weight
Number of subjects: 45
Study 16428539 — intervention group
Group type: EXPERIMENTAL
Intervention: SCH 1 mg/kg lean body weight
Number of subjects: 45